Compare Ecopetrol SA (EC) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecopetrol SA vs Spyre Therapeutics Inc. Common Stock — how do they compare? Ecopetrol SA trades at $17.92 (market cap $33.52B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Ecopetrol SA is far larger — about 4.5× Spyre Therapeutics Inc. Common Stock's market cap, and Ecopetrol SA pays a 3.71% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ecopetrol SA for 84 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| EC | SYRE | |
|---|---|---|
Market Cap | $33.52B | $7.52B |
Volume | 1,602,222 | 1,441,031 |
Sector | Energy | Health |
52-Week High | $18.26 | $108.92 |
52-Week Low | $8.61 | $22.18 |
Typical Hold Time | 84 Days | 0 Days |
Enterprise Value | $62.13B | $6.52B |
Dividend Yield | 3.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ecopetrol (EC) trades at $17.90, up 3.89% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. Revenue has declined from $159.61T in 2022 to $119.69T in 2025, with net income margin falling to 8.76%. Recent management changes and board appointments signal corporate transformation efforts, while analyst consensus is cautious with a 'Reduce' rating and $16.85 price target.
The stock faces headwinds from declining profitability and revenue, offset by low valuation multiples (P/E 8.27, EV/EBITDA 4). Risks include political influence, corruption probes, and oil price volatility. Upside depends on execution under new leadership and stabilization of financials, but current sentiment remains neutral to bearish amid operational challenges.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Ecopetrol SA
Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
